Scholar Rock Secures $36m Investment And Janssen IO Option
This article was originally published in Scrip
Biotech company Scholar Rock has announced a $36m series B financing to fund 2016 plans. Its partner Janssen Biotech, Inc. has also decided to exercise an option in the pair's immune-oncology collaboration.
You may also be interested in...
Gossamer Bio, led by former Receptos CEO Faheem Hasnain and CMO Sheila Gujrathi, revealed $100m in seed and Series A funding during a week in which 17 companies revealed VC rounds totaling $891.2m, giving them good news to discuss during the J.P. Morgan Healthcare conference.
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.